Human Immunodeficiency Virus Disease Associated with Tuberculosis (ICD-11: 1C60)

1. Introduction

Human immunodeficiency virus disease associated with tuberculosis represents one of the most devastating and clinically significant coinfections in contemporary medicine. This condition occurs when a patient with HIV develops active tuberculosis, creating a pathological synergy that dramatically worsens the prognosis of both diseases. HIV progressively compromises the immune system, making the body vulnerable to reactivation of latent Mycobacterium tuberculosis or primary infection by this pathogen.

The clinical importance of this coinfection cannot be underestimated. Tuberculosis remains one of the leading causes of death among people living with HIV, being responsible for a significant proportion of mortality in this population. HIV drastically increases the risk of progression from latent tuberculosis infection to active disease, in addition to modifying the typical clinical presentations of tuberculosis, making diagnosis more challenging.

From a public health perspective, this coinfection represents a complex challenge that requires integrated approaches to prevention, diagnosis, and treatment. The interaction between these two global epidemics creates vicious cycles of transmission and disease, especially in regions with high prevalence of both conditions.

Correct coding of this condition is critical for multiple purposes: it enables precise epidemiological tracking, facilitates appropriate resource allocation, guides public health policies, ensures appropriate reimbursement of services provided, and enables robust clinical research. The code 1C60 in the ICD-11 system was specifically designated to capture this important coinfection.

2. Correct ICD-11 Code

Code: 1C60

Description: Human immunodeficiency virus disease associated with tuberculosis

Parent category: Human immunodeficiency virus disease

This specific code was developed to identify patients who present simultaneously with HIV infection and active tuberculosis. The structure of ICD-11 recognizes the clinical importance of this coinfection by dedicating an exclusive code for its identification, differentiating it from other manifestations of human immunodeficiency virus disease.

Code 1C60 should be applied when there is confirmed documentation of both conditions: HIV infection (regardless of immunological stage or viral load) and active tuberculosis (pulmonary or extrapulmonary). The presence of latent tuberculosis in an HIV-positive patient does not justify the use of this code, requiring evidence of active tuberculous disease.

The categorization within the chapter of human immunodeficiency virus diseases reflects the understanding that tuberculosis, in this context, represents a complication or manifestation of the immunodeficiency caused by the virus. This approach facilitates the identification of patients who require specialized clinical management, involving both antiretroviral therapy and antituberculosis treatment, with all the pharmacological and clinical complexities that this combination entails.

3. When to Use This Code

Code 1C60 should be used in specific clinical scenarios where there is simultaneous confirmation of HIV infection and active tuberculosis. Below, we present detailed practical situations:

Scenario 1: Pulmonary tuberculosis in a patient with known HIV A patient under follow-up for HIV for two years, on antiretroviral therapy, presents with persistent cough for three weeks, evening fever, night sweats, and weight loss. Chest radiography reveals pulmonary infiltrate and sputum smear microscopy is positive for acid-fast bacilli. The diagnosis is confirmed by positive culture for Mycobacterium tuberculosis. This is the classic scenario for using code 1C60, as there is an established diagnosis of HIV and microbiological confirmation of active tuberculosis.

Scenario 2: Simultaneous diagnosis of HIV and tuberculosis A patient seeks care with complaints of prolonged respiratory symptoms and progressive weight loss. During investigation, chest radiography suggests tuberculosis, later confirmed by sputum examination. As part of tuberculosis investigation, HIV testing is performed, which returns positive. In this situation, both diagnoses are established simultaneously, justifying the use of code 1C60 from the moment both conditions are confirmed.

Scenario 3: Extrapulmonary tuberculosis in an HIV-positive patient A patient with a previous diagnosis of HIV presents with progressive cervical lymphadenopathy and fever. Lymph node biopsy reveals caseating granulomas and culture of the material is positive for Mycobacterium tuberculosis, confirming nodal tuberculosis. Even though it is extrapulmonary tuberculosis, code 1C60 is appropriate, as it encompasses all forms of active tuberculosis in patients with HIV.

Scenario 4: Reactivation of latent tuberculosis after HIV diagnosis A patient discovers being HIV positive during investigation of nonspecific symptoms. Three months after diagnosis, still in the process of initiating antiretroviral therapy, develops tuberculous meningitis confirmed by cerebrospinal fluid analysis. Code 1C60 is appropriate to document this serious complication of coinfection.

Scenario 5: Multidrug-resistant tuberculosis in a patient with AIDS A patient in an advanced stage of immunodeficiency (CD4 count below 50 cells/mm³) develops pulmonary tuberculosis. Antimicrobial susceptibility testing reveals resistance to rifampicin and isoniazid. Regardless of the resistance profile, code 1C60 is used, and may be complemented with additional codes that specify drug resistance.

Scenario 6: Disseminated tuberculosis in an HIV-positive patient A patient with HIV presents with prolonged fever, hepatosplenomegaly, and pancytopenia. Investigation reveals disseminated tuberculosis with hepatic, splenic, and bone marrow involvement, confirmed by cultures from multiple sites. This severe form of presentation, typical in patients with advanced immunodeficiency, is also coded as 1C60.

4. When NOT to Use This Code

It is essential to understand the situations in which code 1C60 should not be applied to avoid coding errors:

Latent tuberculosis in HIV-positive patient: When an HIV-positive patient presents with only a positive tuberculin test or IGRA (Interferon Gamma Release Assay), without evidence of active disease, code 1C60 should not be used. In these cases, latent tuberculosis should be coded separately, and HIV should be coded with its specific code without mention of active tuberculosis.

HIV in patient with previous history of cured tuberculosis: If an HIV-positive patient had tuberculosis in the past, completed treatment successfully, and does not present with current active disease, code 1C60 is not appropriate. HIV should be coded without mention of tuberculosis and, if relevant, a code for personal history of tuberculosis should be used.

Unconfirmed suspicion of tuberculosis: When there is only clinical or radiological suspicion of tuberculosis in an HIV-positive patient, but without microbiological or histopathological confirmation, code 1C60 should not be used. In these cases, HIV and suspicion can be coded as symptoms or abnormal findings until diagnostic confirmation.

HIV coinfection with other mycobacteria: HIV-positive patients may develop infections caused by nontuberculous mycobacteria (such as Mycobacterium avium complex). These conditions require different coding and are not appropriate for code 1C60, which is specific for Mycobacterium tuberculosis.

Patient on prophylactic treatment: An HIV-positive patient receiving chemoprophylaxis for tuberculosis (preventive treatment) should not be coded with 1C60, as they do not have active disease. Coding should reflect only HIV status and the use of preventive therapy.

5. Coding Step by Step

Step 1: Assess diagnostic criteria

To correctly use code 1C60, it is necessary to confirm two distinct diagnoses:

HIV confirmation: There must be documentation of positive serological testing for HIV, confirmed by appropriate methodology. Results from rapid tests confirmed by complementary tests, ELISA with confirmation by Western blot, or detectable viral load tests are accepted. The stage of HIV disease is not determinant for the use of the code, and may range from asymptomatic infection to advanced AIDS.

Confirmation of active tuberculosis: Tuberculosis must be confirmed by at least one of the following criteria:

Positive acid-fast bacilli smear microscopy (AFB research in sputum, bronchoalveolar lavage, or other biological materials)
Positive culture for Mycobacterium tuberculosis
Positive molecular test (such as GeneXpert MTB/RIF)
Histopathology compatible with tuberculosis (caseating granulomas) associated with clinical presentation consistent with tuberculosis
Typical radiological findings associated with clinical response to antituberculosis treatment

Step 2: Verify specifiers

Although code 1C60 does not have formal subdivisions in the basic structure, it is important to document:

Tuberculosis location: Specify whether pulmonary, extrapulmonary, or disseminated. This information can be captured through additional codes or in clinical documentation.

Severity of immunodeficiency: Document CD4 lymphocyte count and HIV viral load, as this information is crucial for clinical management and may influence prognosis.

Resistance profile: Identify whether there is drug resistance (multidrug-resistant or extensively drug-resistant tuberculosis), information critical for treatment.

Treatment status: Indicate whether the patient is undergoing treatment, which regimen is being used, and whether there is concomitant use of antiretroviral therapy.

Step 3: Differentiate from other codes

Differentiation from 1C61 (HIV associated with malaria): Code 1C61 is used when the HIV-positive patient develops active malaria, not tuberculosis. The fundamental difference lies in the etiological agent: Mycobacterium tuberculosis versus Plasmodium sp. A patient can, theoretically, have both coinfections simultaneously, requiring both codes. Malaria presents distinct clinical manifestations (cyclic fever, parasitemia documented in thick blood smear or blood smear) and completely different treatment.

Differentiation from 1C62 (HIV without mention of tuberculosis or malaria): This code is used for HIV patients who do not present with active tuberculosis or malaria. It represents the diagnosis of isolated HIV or associated with other complications that are not these two specific infections. If a patient initially coded as 1C62 develops active tuberculosis, the coding must be changed to 1C60. Conversely, after documented cure of tuberculosis, the patient may return to coding 1C62.

Step 4: Required documentation

Checklist of mandatory information:

Date of HIV diagnosis and confirmation method
Date of tuberculosis diagnosis and confirmation method
Anatomical location of tuberculosis
Results of microbiological tests (acid-fast bacilli smear microscopy, culture, molecular tests)
CD4 count and HIV viral load at the time of tuberculosis diagnosis
Antituberculosis treatment regimen prescribed
Status of antiretroviral therapy (if already in use, if started concomitantly, etc.)
Antimicrobial susceptibility profile, when available
Relevant comorbidities that may influence treatment

How to document appropriately: Documentation should be clear and chronological, specifying the dates of each diagnosis. In electronic health records, use structured fields to facilitate coding. Include reports of complementary tests that confirm both diagnoses. Document case discussions in multidisciplinary teams, as the management of this coinfection frequently requires expertise from infectious disease specialists, pulmonologists, and other specialists.

6. Complete Practical Example

Clinical Case:

Initial presentation: A 34-year-old male patient presents to the emergency department with a complaint of productive cough for four weeks, daily afternoon fever, intense night sweats, and weight loss of 8 kilograms in the past month. He also reports progressive asthenia and dyspnea on moderate exertion. He denies known comorbidities and does not have regular medical follow-up. On physical examination, he appears emaciated, with a body mass index of 18 kg/m², tachycardic (heart rate of 102 bpm), febrile (axillary temperature of 38.2°C), and with pulmonary auscultation revealing fine crackles at the right lung apex.

Evaluation performed: Initial tests were requested including chest radiography, which demonstrated a nodular infiltrate in the upper third of the right lung with small cavitation. Complete blood count revealed mild anemia (hemoglobin of 11.2 g/dL) and discrete leukopenia (3,200 leukocytes/mm³). Given the strong suspicion of pulmonary tuberculosis, three sputum samples were collected for smear microscopy, culture, and GeneXpert MTB/RIF molecular testing.

Smear microscopy returned positive (++) in two samples. The GeneXpert test confirmed Mycobacterium tuberculosis with no detection of rifampicin resistance. As part of the tuberculosis investigation protocol, HIV testing was offered, which the patient accepted. The rapid HIV test returned positive, later confirmed by complementary methodology.

Complementary tests for HIV staging revealed CD4 lymphocyte count of 187 cells/mm³ and viral load of 154,000 copies/mL, characterizing advanced immunodeficiency. Additional tests were requested to evaluate possible extrapulmonary tuberculosis, including abdominal ultrasound, which revealed no significant abnormalities.

Diagnostic reasoning: The clinical presentation is highly suggestive of active pulmonary tuberculosis: persistent cough for more than three weeks, afternoon fever, night sweats, and significant weight loss. The radiography with cavitary infiltrate at the lung apex reinforces the suspicion. Microbiological confirmation through positive smear microscopy and molecular testing definitively confirms the diagnosis of active pulmonary tuberculosis.

The simultaneous discovery of HIV infection, with advanced immunodeficiency (CD4 < 200 cells/mm³), establishes the diagnosis of HIV-tuberculosis coinfection. The low CD4 count explains the increased susceptibility to tuberculosis and suggests that HIV may have been present for some time without prior diagnosis.

Coding justification: This case exemplifies perfectly the application of code 1C60, as there is simultaneous confirmation of both conditions: HIV confirmed by appropriate serological tests and active pulmonary tuberculosis confirmed microbiologically. The presence of both active diseases at the time of diagnosis fully justifies the use of this specific code.

Step-by-Step Coding:

Criteria analysis:

Confirmed HIV: Yes (positive rapid test with complementary confirmation)
Confirmed active tuberculosis: Yes (positive smear microscopy and positive GeneXpert)
Both conditions present simultaneously: Yes
Latent tuberculosis only: No (there is active disease)
Previous history of cured tuberculosis: No (it is current active disease)

Code chosen: 1C60 - Human immunodeficiency virus disease associated with tuberculosis

Complete justification: Code 1C60 is the most appropriate because it precisely captures the patient's clinical condition: HIV-tuberculosis coinfection with both diseases in active phase. This code allows for adequate epidemiological tracking of this important coinfection, facilitates integrated clinical management, and ensures that the patient is identified as requiring specialized approach for both conditions.

Applicable complementary codes:

Additional code to specify cavitary pulmonary tuberculosis, if the system allows for greater detail
Code for secondary anemia, if clinically relevant
Procedure codes for antiretroviral therapy and antituberculosis treatment

7. Related Codes and Differentiation

Within the Same Category:

1C61: Human immunodeficiency virus disease associated with malaria

When to use 1C61 vs. 1C60: Code 1C61 should be used when an HIV-positive patient develops active malaria, documented through positive Plasmodium research on thick blood smear or blood film, or through rapid malaria tests. The fundamental difference lies in the etiologic agent causing the coinfection.

Main difference: While 1C60 identifies coinfection with Mycobacterium tuberculosis (chronic bacterial infection, airborne transmission, clinical presentation predominantly respiratory although it can be extrapulmonary), code 1C61 identifies coinfection with Plasmodium sp. (parasitic infection, vector transmission by mosquitoes, clinical presentation with cyclic fever, hemolytic anemia). The treatments are completely distinct: antituberculous versus antimalarial. The epidemiology also differs significantly, with malaria being endemic in specific tropical regions.

1C62: Human immunodeficiency virus disease without mention of tuberculosis or malaria

When to use 1C62 vs. 1C60: Code 1C62 is used for HIV patients who do not present with active tuberculosis or malaria at the time of coding. It applies to asymptomatic HIV-positive patients, patients with other opportunistic infections (such as pneumocystosis, toxoplasmosis, candidiasis), or patients with non-infectious complications of HIV.

Main difference: Code 1C62 is more generic and comprehensive, representing HIV disease without the specific coinfections (tuberculosis or malaria) that have dedicated codes. When a patient coded as 1C62 develops active tuberculosis, the coding should be updated to 1C60. After documented cure of tuberculosis, the patient returns to category 1C62. This distinction is crucial for epidemiologic monitoring and resource allocation, as HIV-tuberculosis coinfection requires specific therapeutic approaches and presents unique clinical challenges.

Differential Diagnoses:

Bacterial pneumonia in HIV-positive patient: Patients with HIV have increased risk of common bacterial pneumonias. Differentiation from tuberculosis can be challenging, but generally bacterial pneumonias have a more acute onset, respond rapidly to conventional antibiotics, and do not present with acid-fast bacilli in sputum. Coding would be HIV (1C62) plus the specific pneumonia code.

Pneumocystosis (Pneumonia by Pneumocystis jirovecii): This opportunistic infection is common in HIV patients with low CD4 count and can mimic tuberculosis with respiratory symptoms, fever, and pulmonary infiltrates. Differentiation is made by identification of the agent (Pneumocystis versus Mycobacterium) and by radiologic pattern (bilateral diffuse interstitial infiltrate in pneumocystosis versus nodular infiltrates or cavitations in tuberculosis).

Lymphoma in HIV-positive patient: Lymphomas are more frequent in HIV patients and can cause similar constitutional symptoms (fever, weight loss, night sweats). Differentiation requires biopsy and histopathologic analysis. An HIV-positive patient with lymphoma would be coded with 1C62 plus the specific lymphoma code.

8. Differences with ICD-10

In ICD-10, the coding of HIV-tuberculosis coinfection used a different approach:

Equivalent ICD-10 codes:

B20.0 - Disease due to HIV resulting in mycobacterial infection
Alternatively, B24 (Disease due to HIV, unspecified) was used combined with tuberculosis codes from the A15-A19 series

Main changes in ICD-11: ICD-11 introduced greater specificity by creating the dedicated code 1C60 exclusively for HIV-tuberculosis coinfection. This change represents a significant advance in recognizing the epidemiological and clinical importance of this specific coinfection.

In ICD-10, there was some ambiguity, as B20.0 included all mycobacteria (tuberculous and non-tuberculous), whereas in ICD-11 tuberculosis receives a specific code (1C60), with better differentiation from other mycobacterioses. The ICD-11 structure also more clearly separates malaria (1C61) from tuberculosis (1C60), while in ICD-10 both could fall under B20 with different subdivisions.

Practical impact of these changes: The greater specificity of ICD-11 allows:

More precise epidemiological tracking of HIV-tuberculosis coinfection
Better identification of patients requiring integrated management
Facilitation of clinical research focused on this specific population
Greater clarity in coding, reducing ambiguities
Better alignment with global HIV and tuberculosis control programs

Professionals accustomed to ICD-10 should be aware of this change, especially when migrating information systems and when analyzing historical data compared with current data.

9. Frequently Asked Questions

1. How is HIV-tuberculosis coinfection diagnosed?

Diagnosis requires independent confirmation of both conditions. For HIV, serological tests (rapid tests, ELISA with confirmation) or viral load tests are used. For tuberculosis, diagnosis is based on microbiological examinations (sputum smear microscopy, culture, molecular tests such as GeneXpert), histopathological examinations showing caseating granulomas, or typical radiological evidence associated with compatible clinical presentation and treatment response. Tuberculosis investigation should always include HIV testing, and vice versa, due to the high frequency of coinfection.

2. Is treatment available in public health systems?

Yes, both antiretroviral therapy and antituberculosis treatment are widely available in public health systems in many countries. International organizations and government programs prioritize access to these essential medications. Tuberculosis treatment typically lasts six months (which may be extended in cases of drug-resistant tuberculosis), while antiretroviral therapy is continuous, for life. Integrated management of coinfection requires careful coordination due to drug interactions and overlapping adverse effects.

3. How long does coinfection treatment last?

Treatment of tuberculosis in HIV-positive patients generally follows the same regimens used in HIV-negative patients, with typical duration of six months for drug-susceptible tuberculosis. However, some specialists recommend extension to nine months in specific cases. Antiretroviral therapy, once initiated, must be maintained indefinitely. The ideal time to initiate antiretroviral therapy in patients with tuberculosis is generally within the first eight weeks of antituberculosis treatment, although the exact timing depends on CD4 count and tuberculosis location.

4. Can this code be used in medical certificates?

The use of ICD codes in medical certificates varies according to local regulations. In many contexts, medical certificates do not include ICD codes to preserve patient confidentiality, especially in sensitive conditions such as HIV. When codes are necessary for administrative or benefits purposes, the ethical and legal implications of disclosing the patient's HIV status should be considered. In some cases, more generic codes or descriptions that do not specifically identify HIV may be used, depending on the purpose of the certificate.

5. Can a patient have latent tuberculosis and HIV without using code 1C60?

Yes, definitely. Code 1C60 is specific for active tuberculosis. An HIV-positive patient with a positive tuberculin test or IGRA, indicating latent tuberculosis infection, but without evidence of active disease, should not be coded with 1C60. In these cases, the HIV code (1C62) and a separate code for latent tuberculosis infection are used. This distinction is important because treatment of latent infection (usually with isoniazid for six to nine months) differs completely from treatment of active tuberculosis.

6. What are the main challenges in managing this coinfection?

The main challenges include: drug interactions between antiretrovirals and antituberculosis agents (especially rifampicin with protease inhibitors and some non-nucleoside reverse transcriptase inhibitors); overlapping adverse effects (hepatotoxicity, peripheral neuropathy); immune reconstitution inflammatory syndrome (IRIS), which can occur when initiating antiretroviral therapy in patients with tuberculosis; dosing complexity with multiple medications; and need for frequent clinical and laboratory monitoring. Treatment adherence is also challenging due to the large number of tablets and long duration.

7. Does tuberculosis in HIV-positive patients present with different manifestations?

Yes, frequently. Patients with advanced immunodeficiency may present with tuberculosis with atypical characteristics: lower frequency of pulmonary cavitations, higher frequency of extrapulmonary or disseminated tuberculosis, negative sputum smear microscopy even with active disease (paucibacillary tuberculosis), and atypical radiological presentations. These differences make diagnosis more challenging and reinforce the importance of maintaining high clinical suspicion and using multiple diagnostic methods.

8. After tuberculosis cure, which code should be used?

After documentation of tuberculosis cure (successful treatment completion, culture negativation, clinical and radiological resolution), the HIV-positive patient should be recoded as 1C62 (HIV without mention of tuberculosis or malaria). The history of previous tuberculosis may be documented separately with an appropriate code for personal history of infectious disease, if relevant to the clinical context. It is important to maintain vigilance for possible recurrence, as HIV-positive patients have increased risk of tuberculosis reinfection or reactivation.

Conclusion

The ICD-11 code 1C60 represents an essential tool for the accurate identification of HIV-tuberculosis coinfection, one of the most challenging combinations in contemporary clinical practice. Proper coding of this condition is fundamental for epidemiological tracking, public health policy planning, resource allocation, and clinical research.

The correct application of this code requires clear understanding of the diagnostic criteria for both diseases, careful differentiation of similar conditions, and complete documentation of clinical characteristics. Healthcare professionals should be aware of the changes introduced by ICD-11 in relation to ICD-10, particularly the greater specificity in coding coinfections.

The management of this coinfection demands a multidisciplinary approach, knowledge of complex drug interactions, and vigilance for complications. Accurate coding is the first step to ensure that these patients receive the integrated and specialized care they need.

External References

This article was prepared based on reliable scientific sources:

References verified on 2026-02-03

Human Immunodeficiency Virus Disease Associated with Tuberculosis

Compartir